Dual-Target Annihilation: New Hope Against Myeloma's Most Vicious Form

A groundbreaking combination of two first-in-class antibody therapies, TALVEY® (talquetamab) and TECVAYLI® (teclistamab), is showing remarkable success against a notoriously aggressive form of multiple myeloma.
Patients with extramedullary disease (EMD), where cancer spreads to soft tissues and organs, demonstrated deep and lasting responses in the pivotal RedirecTT-1 study.
These findings, presented at the 2025 European Hematology Association (EHA) Congress, signal a potential paradigm shift for those facing the poorest prognoses.

For patients battling relapsed or refractory multiple myeloma (RRMM), particularly the formidable extramedullary disease (EMD), the fight has often been a losing one. EMD, where myeloma cells form tumours beyond the bone marrow, has historically defied standard treatments, leaving patients with bleak outlooks and an average overall response rate below 40%⁷.

But now, a beacon of hope emerges. The investigational combination of TALVEY®, targeting the novel GPRC5D, and TECVAYLI®, targeting BCMA, has delivered stunning results in the RedirecTT-1 study – the largest of its kind for EMD patients^{2, 5, 7}. This dual-pronged attack achieved an extraordinary overall response rate (ORR) of 78.9% in these heavily pretreated individuals, with over half experiencing a complete response or better⁷. Even more critically, these responses are proving durable, with 66.2% of responders still holding the disease at bay after a median follow-up of 13.4 months⁷.

This innovative approach, harnessing two distinct mechanisms, aims to outsmart the cancer's escape routes. "Dual targeting of GPRC5D and BCMA may lead to a higher ORR and greater depth of response by mitigating target antigen-related escape," stated Dr. Yael Cohen. The safety profile remained manageable, consistent with individual drug reports, offering a potent new strategy for patients who have exhausted other options, including prior CAR-T therapy^{2, 7, 8}. This heralds a new era in the offensive against one of cancer's most challenging fronts.

Dual-Target Annihilation: New Hope Against Myeloma's Most Vicious Form

References

Stay Updated!